Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4

• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1
• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1

A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/JEqVPLGNfu

• https://x.com/synovialjoints/status/1858615163198599273/photo/1

Did you know? #Lupus arthritis have clinical and US classifications. On MRI, findings will show: - periarticular hyperplastic tissue - capsular swelling - edematous tenosynovitis @RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/EoKh2Q3V9Z

• https://x.com/RHEUMarampa/status/1858615615248101855/photo/1
• https://x.com/RHEUMarampa/status/1858615615248101855/photo/1

McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses shown in picture. Good efficacy across domains, but this is phase 2, will await the phase 3. @RheumNow #ACR24 Abstr#2582 https://t.co/FQflZMPes0 https://t.co/DATqo37yib

• Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanob…
• https://x.com/RichardPAConway/status/1858577160186814616/photo/1

A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK

• https://x.com/ericdeinmd/status/1858577759452180634/photo/1
• https://x.com/ericdeinmd/status/1858577759452180634/photo/1

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

• https://x.com/RHEUMarampa/status/1858580860238217419/photo/1

Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG

• Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and…
• https://x.com/RichardPAConway/status/1858581438398165289/photo/1

Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt

• https://x.com/KDAO2011/status/1858582025466175719/photo/1
• https://x.com/KDAO2011/status/1858582025466175719/photo/1

A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc

• https://x.com/ericdeinmd/status/1858581617067127217/photo/1

A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe

• https://x.com/ericdeinmd/status/1858584654712017059/photo/1
• https://x.com/ericdeinmd/status/1858584654712017059/photo/1

Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣 #ACR24 @RheumNow Abstr#2584 #ACRbest https://t.co/t0y6C618ll

• https://x.com/EBRheum/status/1858585213095604473/photo/1

A#2585 PsABIOnd observ cohort study of IL23 (GUS) or IL17i 6 mo interim results of 686 pts PROs: PsAID-12 High Rx persistence at 6mo -94% on both Rx Comparable improvement in PsAID-12 - best results skin, discomfort 1/2 with clinically meaningful improvement #ACR24 @RheumNow https://t.co/TM1jwTRR7C

• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1

Dr. CStone et al. assessed nailfold dermoscopy in distinguishing DM from SLE Almost all DM pts had nailfold changes in at least 1 digit vs. SLE & majority of DM pts had nailfold changes in all 10 digits Dermoscopy is a simple alternative to capillaroscopy @rheumNow #ACR24 ab2404 https://t.co/6tEXAlX7lt

• https://x.com/RHEUMarampa/status/1858589997844033617/photo/1

A systematic review & meta-analysis by Dr. JBCorrea et al show that the ff immune-mediated dses are assocd w/⬆️ ocurrence risk after covid19 infection 👇 Behcets SpA SS SLE PMR Pso RA Sjogrens T1DM Vasculitis IBD Ask prior covid infexn in pts history @RheumNow #ACR24 abs2614 https://t.co/TIEglPrmvL

• https://x.com/RHEUMarampa/status/1858590128110784622/photo/1

Neuropsychiatric manifestations in SLE. Susanne Benseler MD @RheumNow #ACR24 https://t.co/subiykC5Q4

• https://x.com/synovialjoints/status/1858591546930794555/photo/1